Biotech Stocks Facing FDA Decision In February 2025
February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals rose after Journavx, the company's oral non-opioid pain medication, received Food and Drug Administration approval. The Boston company's stock rose 4.3%, to $457.25, ...
Axsome Shares Up Post Market After Hitting Record High on FDA Approval
Symbravo, for the acute treatment of migraine with or without aura in adult patients, showed superior efficacy across a broad range of severity, Axsome said Thursday. A single oral dose gave patients ...
Vertex gets FDA approval for non-opioid pain reliever
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) rose 3% in post-market trading Thursday on news the company had received FDA ...
First New Non-Opioid Painkiller in Decades Gets FDA Approval
Vertex Pharmaceuticals won U.S. approval for the first new non-opioid painkiller in decades, which could be a blockbuster if the company can persuade insurers and doctors to embrace the non-addictive ...
Clene Inc. secures additional NIH grant funds for ALS therapy
Salt Lake City-based pharmaceutical company Clene Inc. has amended its grant subaward with Columbia University, securing up ...
Eagle-Tribune6h
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025
We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...
FDA approves Vertex's first-in-class non-opioid analgesic for acute pain
Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug is a non-opioid ...
Axsome gets FDA approval for Symbravo for migraine
Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or ...
manilatimes8h
60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company”), a pharmaceutical company focused on developing new ...
Earnings call transcript: Else Nutrition Q1 2022 shows strong growth
Else Nutrition Holdings Inc (ELSE) reported a robust start to 2022 with significant revenue growth and improved profitability ...